Literature DB >> 1535906

Clinically occult avascular necrosis of the hip: prevalence in an asymptomatic population at risk.

O Tervonen1, D M Mueller, E L Matteson, J A Velosa, W W Ginsburg, R L Ehman.   

Abstract

An abbreviated screening magnetic resonance (MR) imaging examination was used to determine the prevalence of clinically occult avascular necrosis (AVN) of the hip in 100 asymptomatic renal transplantation patients treated with corticosteroids. All patients were more than 18 years old, had been treated with corticosteroids for at least 6 months, and had no symptoms of AVN before MR imaging. Of the 100 patients screened, six were found to have clinically occult AVN at MR imaging (rate: 6%, with a 95% confidence interval of 2.2%-12.6%). No significant differences were found regarding the total dose of corticosteroids and exposure time between patients with and patients without asymptomatic AVN. The authors conclude that there is a significant prevalence of asymptomatic, clinically occult AVN among renal transplantation patients treated with corticosteroids and that a potentially low-cost screening MR imaging examination can be used to detect such disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1535906     DOI: 10.1148/radiology.182.3.1535906

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  11 in total

Review 1.  In brief: Ficat classification: avascular necrosis of the femoral head.

Authors:  Muhammad Umar Jawad; Abdul Ahad Haleem; Sean P Scully
Journal:  Clin Orthop Relat Res       Date:  2012-09       Impact factor: 4.176

2.  Prevalence and Associations of Avascular Necrosis of the Hip in a Large Well-characterized Cohort of Patients With Inflammatory Bowel Disease.

Authors:  Vineet S Rolston; Anish V Patel; Thomas J Learch; Dalin Li; Dmitry Karayev; Chadwick Williams; Madhavi L Siddanthi; Stephan R Targan; Michael H Weisman; Dermot P B McGovern
Journal:  J Clin Rheumatol       Date:  2019-01       Impact factor: 3.517

Review 3.  Steroid induced osteonecrosis: An analysis of steroid dosing risk.

Authors:  Christian Powell; Christopher Chang; Stanley M Naguwa; Gurtej Cheema; M Eric Gershwin
Journal:  Autoimmun Rev       Date:  2010-07-09       Impact factor: 9.754

4.  The prevalence and natural history of early osteonecrosis (ON) of the femoral head.

Authors:  B D Mulliken; D L Renfrew; R A Brand; C G Whitten
Journal:  Iowa Orthop J       Date:  1994

5.  Does statin usage reduce the risk of corticosteroid-related osteonecrosis in renal transplant population?

Authors:  Muhammad Ajmal; A J Matas; Michael Kuskowski; Edward Y Cheng
Journal:  Orthop Clin North Am       Date:  2009-04       Impact factor: 2.472

6.  Incidence and predictors of osteonecrosis among cyclosporin- or tacrolimus-treated renal allograft recipients.

Authors:  Masaki Takao; Takashi Sakai; Takashi Nishii; Hideki Yoshikawa; Shiro Takahara; Nobuhiko Sugano
Journal:  Rheumatol Int       Date:  2009-10-28       Impact factor: 2.631

7.  Avascular osteonecrosis in kidney transplant recipients: Risk factors in a recent cohort study and evaluation of the role of secondary hyperparathyroidism.

Authors:  Renaud Felten; Peggy Perrin; Sophie Caillard; Bruno Moulin; Rose-Marie Javier
Journal:  PLoS One       Date:  2019-02-22       Impact factor: 3.240

Review 8.  High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature Review.

Authors:  Michael A Mont; Robert Pivec; Samik Banerjee; Kimona Issa; Randa K Elmallah; Lynne C Jones
Journal:  J Arthroplasty       Date:  2015-04-08       Impact factor: 4.757

9.  Avascular necrosis of bone in severe acute respiratory syndrome.

Authors:  N Hong; X K Du
Journal:  Clin Radiol       Date:  2004-07       Impact factor: 2.350

Review 10.  Beware of Steroid-Induced Avascular Necrosis of the Femoral Head in the Treatment of COVID-19-Experience and Lessons from the SARS Epidemic.

Authors:  Shenqi Zhang; Chengbin Wang; Lei Shi; Qingyun Xue
Journal:  Drug Des Devel Ther       Date:  2021-03-04       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.